BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis (apixaban).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

BMS sues MSN over Pomalyst generic

7 April 2022 Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.

Big Pharma

Pfizer accuses ex-employees of stealing trade secrets for startup

3 February 2022 Pfizer has sued two of its former executive staffers, alleging that they stole trade secrets related to diabetes medication before leaving the company.

Americas

Bristol Myers can’t convince circuit to overturn $1.2bn ruling

18 January 2022 The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

More on this story

Editor's picks

Editor's picks

More features